GlassScriptPhysician profile
Dongyan Liu
NPI 1912391913
$3,728.85
in general payments reported to CMS, 2019-2025
29 companies · $869 in 2025
The $869 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $624 · 2024: $2,111 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,381 · Travel and Lodging: $1,219 · Education: $4.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,380.94 |
| Travel and Lodging | $1,218.60 |
| Education | $4.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $1,837.60 | 2024 | |
| Janssen Biotech, INC. | $244.57 | 2023-2025 | Tecvayli, Darzalex, Carvykti |
| Astrazeneca Pharmaceuticals LP | $190.56 | 2023-2025 | Lynparza, Calquence |
| Daiichi Sankyo INC. | $142.43 | 2024-2025 | Enhertu |
| Gilead Sciences, INC. | $135.35 | 2023-2025 | Trodelvy |
| Beigene USA, INC. | $133.50 | 2024 | Brukinsa |
| Mirati Therapeutics, INC. | $131.64 | 2023 | Krazati |
| Stemline Therapeutics INC. | $131.44 | 2025 | Orserdu |
| Eisai INC. | $122.73 | 2022-2025 | |
| Celgene Corporation | $84.66 | 2023-2025 | Reblozyl |
| Pfizer INC. | $58.82 | 2025 | |
| Abbvie INC. | $56.25 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $47.55 | 2025 | |
| Glaxosmithkline, LLC. | $37.63 | 2025 | Jemperli, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $31.05 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $28.93 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $28.61 | 2025 | Libtayo |
| Myriad Genetic Laboratories, INC. | $27.71 | 2024 | Mychoice Cdx |
| Pharmacosmos Therapeutics INC. | $27.35 | 2025 | Monoferric |
| Beone Medicines USA, INC. | $27.35 | 2025 | Tevimbra |
| Array Biopharma INC | $27.20 | 2025 | Braftovi, Mektovi |
| Tolmar, INC. | $27.15 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $27.15 | 2025 | Rubraca |
| Exelixis INC. | $27.13 | 2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $24.57 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Caris Mpi, INC. | $20.68 | 2025 | Mi Cancer Seek |
| Tempus Ai, INC | $18.23 | 2025 | Xt Cdx |
| Puma Biotechnology, INC. | $15.86 | 2025 | |
| Adc Therapeutics America, INC. | $15.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dongyan Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.